ONE MAIN STREET, CAMBRIDGE, MA
New Drug Application Submission Initiated for Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under Real-Time Oncology Review Program
Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Zipalertinib and Chemotherapy Show 6-Month Survival Benefit in REZILIENT3 Trial
Zipalertinib and Chemotherapy Achieve PFS Endpoint in REZILIENT3 Trial
Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Stockholders Elect Directors and Ratify KPMG as Auditor at Annual Meeting
Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Correspondence
Submission Upload